Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2012
04/17/2012CA2566544C Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
04/17/2012CA2566380C Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor
04/17/2012CA2559630C Fasudil-containing preparation and method of improving stability thereof
04/17/2012CA2555759C Hyaluronic acid derivative and drug containing the same
04/17/2012CA2552607C Cosmetic composition and method for retarding hair growth
04/17/2012CA2542854C Graduated estrogen contraceptive
04/17/2012CA2537826C Imidazole derivatives
04/17/2012CA2537450C Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
04/17/2012CA2537044C Solid dispersions comprising tacrolimus
04/17/2012CA2529351C Use of prostaglandin i for enhancing the effect of a renin-angiotensin system inhibitor on a renal disease
04/17/2012CA2528710C A method of treating an anxiety disorder
04/17/2012CA2525273C Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
04/17/2012CA2517429C Process for manufacturing a pharmaceutical composition in the form of tablets containing a fibrate and the tablets obtained through the process
04/17/2012CA2516589C Hiv replication inhibiting pyrimidines and triazines
04/17/2012CA2515384C Medicament for inhibiting tumour growth
04/17/2012CA2513717C Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
04/17/2012CA2511595C Optically active dihydropyridine derivative
04/17/2012CA2508312C Treatment of inflammatory disorders with 2,3-benzodiazepines
04/17/2012CA2495275C Aerosol formulation for inhalation comprising an anticholinergic agent
04/17/2012CA2494987C Isoxazoles and their use as modulators of metabotropic glutamate receptor-5
04/17/2012CA2493843C Azolidinone-vinyl fused-benzene derivatives
04/17/2012CA2491680C Inhibitors of ftsz and uses thereof
04/17/2012CA2488120C Pharmaceutical composition for improving cerebral function and method for improving cerebral function
04/17/2012CA2487699C A buffered, liquid nicotine composition for pulmonary administration
04/17/2012CA2483826C Epothilone derivative for the treatment of hepatoma and other cancer diseases
04/17/2012CA2481521C Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
04/17/2012CA2474163C Novel elongase gene and method for producing polyunsaturated fatty acids
04/17/2012CA2474104C N-oxides of n-phenyl-2-pyrimidine-amine derivatives
04/17/2012CA2469138C Inhibitors of cytosolic phospholipase a2
04/17/2012CA2468948C Preventives or remedies for alzheimer's disease or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
04/17/2012CA2467110C Inclusion complex of paclitaxel with 2-hydroxypropyl-beta-cyclodextrin
04/17/2012CA2450007C Compounds and methods for the treatment or prevention of flavivirus infections
04/17/2012CA2445654C Anastomosis devices and methods for treating anastomotic sites
04/17/2012CA2427844C Naphthalene derivatives
04/17/2012CA2410526C Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
04/17/2012CA2408380C Recombinant human cln2 protein and methods of its production and use
04/17/2012CA2408328C Immunogenic polypeptides encoded by mage minigenes and uses thereof
04/17/2012CA2407806C Use of heparin or nonanticoagulant heparin for inhibiting apoptosis arising from ischemia perfusion injury
04/17/2012CA2402894C Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method
04/17/2012CA2377607C Neurotrophic factor receptor
04/17/2012CA2373290C Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
04/17/2012CA2371625C Polyamines and their use in therapy
04/17/2012CA2361070C Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
04/17/2012CA2177195C Method and composition for treating renal failure
04/17/2012CA2145778C Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
04/12/2012WO2012048330A2 Treatment of motor neuron disease
04/12/2012WO2012048294A2 Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
04/12/2012WO2012048289A1 Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
04/12/2012WO2012048285A1 Delivery of bisphosphonates by microinjection systems
04/12/2012WO2012048271A1 Phosphoramidate derivatization of inorganic polyphosphates and methods
04/12/2012WO2012048265A2 Methods of treating inflammation
04/12/2012WO2012048259A2 Substituted pyridazine carboxamide compounds
04/12/2012WO2012048258A2 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
04/12/2012WO2012048243A2 Depression disorder therapeutics with creatine analogs
04/12/2012WO2012048235A1 Vitamin e formulations of sulfamide ns3 inhibitors
04/12/2012WO2012048214A2 Use of hyaluronan for promoting angiogenesis
04/12/2012WO2012048204A2 Prodrugs utilizing a transporter directed uptake mechanism
04/12/2012WO2012048202A2 Method of preparation of antiviral compounds and useful intermediates thereof
04/12/2012WO2012048181A1 Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
04/12/2012WO2012048164A2 Porphyrin treatment of neurodegenerative diseases
04/12/2012WO2012048129A2 Inhibitors of polo-like kinase
04/12/2012WO2012048119A2 Anti-biofilm compositions and methods for using
04/12/2012WO2012048059A2 Bepotastine compositions
04/12/2012WO2012048058A2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
04/12/2012WO2012048045A1 Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
04/12/2012WO2012048043A1 Methods of making l-ornithine phenyl acetate
04/12/2012WO2012048013A2 Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
04/12/2012WO2012047993A2 N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv
04/12/2012WO2012047966A2 Compositions and methods for treating ocular edema, neovascularization and related diseases
04/12/2012WO2012047956A2 Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
04/12/2012WO2012047948A1 New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid
04/12/2012WO2012047926A2 Sulfonamide-containing compounds
04/12/2012WO2012047918A1 Anti-epileptogenic agents
04/12/2012WO2012047907A1 Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
04/12/2012WO2012047893A2 Use of rifazil and analogues thereof to treat ocular disorders
04/12/2012WO2012047871A1 Polymorphs of saxagliptin hydrochloride and processes for preparing them
04/12/2012WO2012047870A2 Antimicrobial preservation of propofol emulsions
04/12/2012WO2012047856A2 Novel inhibitors of secretion of hepatitis b virus antigens
04/12/2012WO2012047852A2 Compositions and methods for modulating immunodeficiency virus transcription
04/12/2012WO2012047848A2 Allergen deactivator composition, articles and methods
04/12/2012WO2012047845A1 Bortezomib formulations stabilised with boric
04/12/2012WO2012047826A2 Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
04/12/2012WO2012047813A1 Macrocyclic lactone compounds and methods for their use
04/12/2012WO2012047800A1 Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend
04/12/2012WO2012047775A1 Pharmaceutical combinations
04/12/2012WO2012047772A2 Imidazole derivatives
04/12/2012WO2012047764A1 Therapeutic antiviral peptides
04/12/2012WO2012047763A2 Stimulation of neuroregeneration by flavonoid glycosides
04/12/2012WO2012047733A2 Treatment of acne by conditioned media
04/12/2012WO2012047706A2 Methods for promotiing reinnervation of auditory hair cells
04/12/2012WO2012047703A2 Cyclopropyl-spiro-piperidines useful as sodium channel blockers
04/12/2012WO2012047702A1 Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
04/12/2012WO2012047699A1 Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
04/12/2012WO2012047674A2 Methods and compositions for disease treatment using inhalation
04/12/2012WO2012047656A1 Lipid a analog compositions
04/12/2012WO2012047645A2 Combination treatment for rosacea
04/12/2012WO2012047630A2 N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
04/12/2012WO2012047628A2 Methods of managing blood sugar levels and compositions related thereto
04/12/2012WO2012047617A1 Selective androgen receptor modulators
04/12/2012WO2012047587A2 Mdm2 inhibitors for treatment of ocular conditions
1 ... 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 ... 7860